Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153236 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDKEAP1NFE2L2 | |
| SCHEMBL6154514 | 0.89 | HRH1 (0.50) | ALDH1A1KDM4EKEAP1NFE2L2HSP90AA1 | |
| SCHEMBL6154507 | 0.89 | HRH1 (0.50) | ALDH1A1KDM4EKEAP1NFE2L2HSP90AA1 | |
| SCHEMBL6152429 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP2C19POLBL3MBTL1 | |
| SCHEMBL5322002 | 0.76 | MEN1 (0.53) | ALDH1A1KDM4EPOLBL3MBTL1DRD1 | |
| SCHEMBL6548977 | 0.75 | PLK1 (0.47) | ALDH1A1KDM4EHPGDPOLBL3MBTL1 | |
| SCHEMBL6548980 | 0.75 | PLK1 (0.47) | ALDH1A1KDM4EHPGDPOLBL3MBTL1 | |
| SCHEMBL27466067 | 0.75 | ABCB1 (0.52) | ALDH1A1KDM4EKEAP1NFE2L2POLB | |
| SCHEMBL9157528 | 0.74 | MAPT (0.52) | ALDH1A1KDM4EHPGDKEAP1NFE2L2 | |
| SCHEMBL9157538 | 0.74 | MAPT (0.52) | ALDH1A1KDM4EHPGDKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| EP-1307449-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | ALDH1A1 1798/4885KDM4E 1330/4885HPGD 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.